Regeneron Inks US$2.01 B Deal for Hansoh’s Late-Stage Obesity Drug Candidate
By Hitesh Udar
Pharma Deals Review: Vol 2025 Issue 6 (Table of Contents)
Published: 16 Jun-2025
DOI: 10.3833/pdr.v2025.i6.2952 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Regeneron Pharmaceuticals has entered into a strategic licensing agreement with China’s Hansoh Pharmaceutical to advance its next-generation obesity and metabolic therapies...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS